Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 1364Lung Neoplasms 697Small Cell Lung Carcinoma 202Neoplasms 151Neoplasm Metastasis 130Breast Neoplasms 116Melanoma 99Colorectal Neoplasms 84Adenocarcinoma of Lung 84Ovarian Neoplasms 78Pancreatic Neoplasms 72Carcinoma, Renal Cell 69Head and Neck Neoplasms 66Mesothelioma 58Prostatic Neoplasms 53Urinary Bladder Neoplasms 52Mesothelioma, Malignant 51Stomach Neoplasms 47Triple Negative Breast Neoplasms 45Carcinoma 45Esophageal Neoplasms 43Brain Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Colonic Neoplasms 35Sarcoma 34Adenocarcinoma, Bronchiolo-Alveolar 33Recurrence 32Adenocarcinoma 31Uterine Cervical Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 29

Interventions

Fluticasone-Salmeterol Drug Combination 1Fluticasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bronchial Hyperreactivity × Thoracic × Clear all
NCT00455923 2018-02-05

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

GlaxoSmithKline

Phase 4 Completed
100 enrolled 8 charts
LymphoidThoracic

Asthma, Lymphoma, Follicular, Bronchial Hyperreactivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡